Le Lézard
Classified in: Health, Science and technology

Genomenon Awarded NIH NHGRI Grant to Curate the Human Genome


ANN ARBOR, Mich., Feb. 15, 2022 /PRNewswire-PRWeb/ -- Genomenon, Inc., an AI-driven genomics company, today announced that it was awarded a $1.7 million grant by the National Institutes of Health (NIH) through the Small Business Innovation Research (SBIR) program. The grant is to accelerate development of the Mastermind® Genomic Search Engine, the company's AI-driven variant interpretation engine, with a vision of curating the entire human genome. The grant enables Genomenon to increase the expertly curated evidence needed for clinicians to make a genetic diagnosis, extending Mastermind beyond its current function as the most complete source of genomic information for medical research.

The NIH's SBIR program focuses on a variety of high-impact technologies spanning research tools, diagnostics, digital health, drugs, and medical devices. It provides funding needed to bring scientific innovations from bench to bedside. Awarded by the NIH's National Human Genome Research Institute, this grant will fund the continued evolution of Genomenon's AI-driven genomic engine, as well as the incorporation of collaborative features for community-based variant interpretation¹.

"Having already curated more than 250 genes for rare diseases and cancer, this NIH funding allows us to accelerate the pace of genetic interpretation for our AI-driven curation engine, which is a crucial first step in a process that enables targeted and efficient use of expert human curators," said Mike Klein, CEO of Genomenon. "Next-generation sequencing gives us the ability to quickly and efficiently create a large amount of genomic data. Curating the entire genome for meaning and actionability at scale is the next step in the evolution of using this information to improve patient care."

Mastermind is the world's most comprehensive source for genomic literature in the variant interpretation space. Used by more than 1,000 diagnostic labs and integrated into 18 clinical-grade decision support platforms and reference databases across the globe, Mastermind connects patient genetic data with critical evidence from scientific literature needed to diagnose rare genetic diseases and cancer.

About Genomenon

Genomenon is an AI-driven genomics company that organizes the world's genomic knowledge to connect patient DNA to scientific research in the diagnosis and development of treatments for patients with rare genetic diseases and cancer.

For more information, visit Genomenon.com
_________________________________________

1. Research reported in this publication was supported by the National Human Genome Research Institute of the National Institutes of Health under Award Number R43HG010446. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Media Contact

Candace Chapman, Genomenon, 1-734-219-5175, [email protected]

 

SOURCE Genomenon


These press releases may also interest you

at 13:54
INOVAIT, the national network for commercializing breakthroughs in image-guided therapy (IGT) and artificial intelligence, presented the inaugural INOVAIT awards at its annual Discovery Forum last week (April 18, 2024). The awards were established to...

at 13:53
Medical device innovator and worldwide leader in minimally invasive neurosurgery NICO Corporation is launching its latest product innovation at next week's American Association of Neurosurgical Surgeons (AANS) Annual Scientific Meeting in Chicago,...

at 13:50
According to Arizton's latest focus research report, the US medical bathtubs market is growing at a CAGR of 2.27% during 2023-2029....

at 13:44
CellFE Inc., a life sciences tools company with a novel microfluidics-based cellular engineering platform, announced today an upcoming presentation by CSO Todd Sulchek, PhD, at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting,...

at 13:33
EHN Canada proudly announces a significant regional expansion of EHN Bellwood's legacy in pioneering addiction and mental health treatment centres....

at 13:30
CARBIOS celebrates the groundbreaking of its PET biorecycling plant, a world first, with its partners CARBIOS' first plant is also a world first using revolutionary enzymatic depolymerization technology, marking a major step forward in the...



News published on and distributed by: